title: A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis.
abstract: CONCLUSIONS
  In this study, octreotide was not found to be of benefit in the treatment of acute pancreatitis.
  
  
  BACKGROUND
  Somatostatin and its long-acting analog octreotide have both been proposed for the treatment of patients with acute pancreatitis, but neither agent has been adequately assessed in patients with severe attacks.
  
  
  METHODS
  Fifty-eight patients with moderate or severe acute pancreatitis who were admitted to hospitals within the west of Scotland over an 18-mo period were randomized to receive octreotide, 40 micrograms/h, by continuous i.v. infusion for 5 d, or placebo in addition to standard supportive therapy.
  
  
  RESULTS
  There was no significant difference in the incidence of complications (54% octreotide group and 40% placebo group) or mortality (octreotide group 18%; placebo group 20%).
authors.affiliation: Department of Surgery, Glasgow Royal Infirmary, UK.
authors.forename: C
authors.initials: C
authors.lastname: McKay
authors.forename: J
authors.initials: J
authors.lastname: Baxter
authors.forename: C
authors.initials: C
authors.lastname: Imrie
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000009:adverse effects / Q000627:therapeutic use*; D010195:Pancreatitis / Q000188:drug therapy* / Q000401:mortality
chemical_list: D015282:Octreotide